Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data

European Urology

Volumn 64, Issue 5, 2013, Pages 846-854

  Burger, Maximilian ^a   Grossman, H Barton ^b   Droller, Michael ^c   Schmidbauer, Joerg ^d   Hermann, Gregers ^e   Drǎgoescu, Octavian ^f   Ray, Eleanor ^g   Fradet, Yves ^h   Karl, Alexander ⁱ   Burgués, Juan Pablo ^j   Witjes, J Alfred ^k   Stenzl, Arnulf ^l   Jichlinski, Patrice ^m   Jocham, Dieter ⁿ  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e FREDERIKSBERG HOSPITAL   (Denmark)

^f Craiova Clinical Hospital   (Romania)

^g GUY S HOSPITAL   (United Kingdom)

^h LAVAL UNIVERSITY   (Canada)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ UNIVERSITY OF LÜBECK   (Germany)

more..

Author keywords

Bladder cancer; HAL blue light cystoscopy; Hexaminolevulinate

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ARTICLE; CANCER DIAGNOSIS; CYSTOSCOPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; META ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PHOTODYNAMICS; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SYSTEMATIC REVIEW; TUMOR RECURRENCE; WHITE LIGHT;

BLADDER CANCER; HAL BLUE LIGHT CYSTOSCOPY; HEXAMINOLEVULINATE;

AMINOLEVULINIC ACID; CARCINOMA IN SITU; CYSTOSCOPY; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84885429377     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.059     Document Type: Article

References (39)

1. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
2. J.A. Witjes, L.A. Kiemeney, G.O. Oosterhof, and F.M. Debruyne Prognostic factors in superficial bladder cancer. A review Eur Urol 21 1992 89 97
3. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
4. R. Klaen, V. Loy, and H. Huland Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder J Urol 146 1991 316 318
5. H. Mostafid, and M. Brausi Measuring and improving the quality of transurethral resection for bladder tumour (TURBT) BJU Int 109 2012 1579 1582
6. M. Babjuk, V. Soukup, R. Petrik, M. Jirsa, and J. Dvorácek 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer BJU Int 96 2005 798 802
7. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
8. D. Jocham, F. Witjes, and S. Wagner Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study J Urol 174 2005 862 866
9. T. Filbeck, U. Pichlmeier, R. Knüchel, W.F. Wieland, and W. Roessler Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumours J Urol 168 2002 67 71
10. G. Jakse, F. Algaba, P.U. Malmstrom, and W. Oosterlink A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45 2004 539 546
11. K.U. Köhrmann, M. Woeste, J. Kappes, J. Rassweiler, and P. Alken The value of secondary transurethral resection for superficial bladder tumors Akt Urol 25 1994 208 213
12. J. Schmidbauer, F. Witjes, M. Schneller, R. Donat, M. Susani, and M. Marberger Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
13. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
14. P. Shen, J. Yang, and W. Wei Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis BJU Int 110 2012 E209 E215
15. M. Brausi, J.A. Witjes, and D. Lamm A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group J Urol 186 2011 2158 2167
16. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Controlled Clin Trials 7 1986 177 188
17. B. Geavlete, R. Multescu, D. Georgescu, M. Jecu, F. Stanescu, and P. Geavlete Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109 2012 549 556
18. Y. Fradet, H.B. Grossman, and L. Gomella A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study J Urol 178 2007 68 73
19. H.B. Grossman, L. Gomella, and Y. Fradet A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178 2007 62 67
20. H.B. Grossman, A. Stenzl, and Y. Fradet Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
21. A. Stenzl, M. Burger, and Y. Fradet Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer J Urol 184 2010 1907 1913
22. P. Jichlinski, L. Guillou, and S. Karlsen Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study J Urol 170 2003 226 229
23. J.P. Burgués, G. Conde, and J. Oliva Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group [in Spanish] Actas Urol Esp 35 2011 439 445
24. G.G. Hermann, K. Mogensen, S. Carlsson, N. Marcussen, and S. Dunn Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study BJU Int 108 2011 E297 E303
25. O. Drǎgoescu, P. Tomescu, and A. Pǎnuş Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid Rom J Morphol Embryol 52 2011 123 127
26. E.R. Ray, K. Chatterton, K. Thomas, M.S. Khan, A. Chandra, and T.S. O'Brien Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer J Endourol 23 2009 983 988
27. A. Lapini, A. Minervini, and A. Masala A comparison of hexaminolevulinate (Hexvix(R)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study Surg Endosc 26 2012 3634 3641
28. T. Karaolides, A. Skolarikos, and A. Bourdoumis Hexaminolevulinate- induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80 2012 354 360
29. B. Geavlete, M. Jecu, R. Multescu, D. Georgescu, and P. Geavlete HAL blue-light cystoscopy in high-risk non-muscle invasive bladder cancer - re-TURBT recurrence rates in a prospective, randomized study Urology 76 2010 664 669
30. S.P. Lerner, H. Liu, M.-F. Wu, Y.K. Thomas, and J.A. Witjes Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder Urol Oncol 30 2012 285 289
31. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
32. J.M. Abascal Junquera, M. Hevia Suarez, J.M. Abascal Garcia, C. Estebanez, A. Astudillo, and R. Abascal Initial experience in the diagnosis and treatment of superficial bladder tumours with Hexvix(R) Arch Esp Urol 61 2008 475 483
33. F. Saint, V. Elalouf, R. Spie, C. Cordonnier, H. Sevestre, and J. Petit Prospective monocentric evaluation of bladder tumor targeting by Hexvix fluorescence: preliminary results Prog Urol 20 2010 644 650
34. P. Stanislaus, D. Zaak, and T. Stadler Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate World J Urol 28 2010 407 411
35. D. Vordos Photodynamic diagnosis (cystoscopy with hexaminolevulinate) in the surveillance of urothelial lesions managed with conservative treatment Ann Pathol 5 2010 115 116
36. E.R. Ray, K. Chatterton, and M.S. Khan Hexulaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin BJU Int 105 2010 789 794
37. B. Geavlete, R. Multescu, D. Georgescu, and P. Geavlete Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors J Endourol 23 2009 977 981
38. J.A. Witjes, P.M. Moonen, and A.G. van der Heijden Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study Eur Urol 47 2005 319 322
39. W. Loidl, J. Schmidbauer, M. Susani, and M. Marberger Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 47 2005 323 326